AIM IMMUNOTECH Valuation
| AIM Stock | USD 0.09 0.02 13.73% |
AIM IMMUNOTECH seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of AIM IMMUNOTECH INC from examining the firm fundamentals such as Current Valuation of 5.11 M, return on equity of -3.89, and Operating Margin of (130.11) % as well as evaluating its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that AIM IMMUNOTECH's price fluctuation is very steady at this time. Calculation of the real value of AIM IMMUNOTECH INC is based on 3 months time horizon. Increasing AIM IMMUNOTECH's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the AIM stock is determined by what a typical buyer is willing to pay for full or partial control of AIM IMMUNOTECH INC. Since AIM IMMUNOTECH is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AIM Stock. However, AIM IMMUNOTECH's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0949 | Real 0.0911 | Hype 0.09 | Naive 0.0893 |
The intrinsic value of AIM IMMUNOTECH's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AIM IMMUNOTECH's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AIM IMMUNOTECH INC helps investors to forecast how AIM stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AIM IMMUNOTECH more accurately as focusing exclusively on AIM IMMUNOTECH's fundamentals will not take into account other important factors: AIM IMMUNOTECH Total Value Analysis
AIM IMMUNOTECH INC is presently forecasted to have company total value of 5.11 M with market capitalization of 6.52 M, debt of 2.94 M, and cash on hands of 27.05 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the AIM IMMUNOTECH fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.11 M | 6.52 M | 2.94 M | 27.05 M |
AIM IMMUNOTECH Investor Information
The company recorded a loss per share of 0.31. AIM IMMUNOTECH INC last dividend was issued on the 11th of June 2019. The entity had 1:44 split on the 11th of June 2019. AIM IMMUNOTECH INC is not in a good financial situation at this time. It has a very high probability of going through financial hardship in August.AIM IMMUNOTECH Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AIM IMMUNOTECH has an asset utilization ratio of 1.97 percent. This suggests that the Company is making $0.0197 for each dollar of assets. An increasing asset utilization means that AIM IMMUNOTECH INC is more efficient with each dollar of assets it utilizes for everyday operations.AIM IMMUNOTECH Ownership Allocation
AIM IMMUNOTECH holds a total of 68.75 Million outstanding shares. AIM IMMUNOTECH INC shows 6.9 percent of its outstanding shares held by insiders and 11.06 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.AIM IMMUNOTECH Profitability Analysis
The company reported the last year's revenue of 170 K. Reported Net Loss for the year was (17.32 M) with profit before taxes, overhead, and interest of 139 K.About AIM IMMUNOTECH Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of AIM IMMUNOTECH INC. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of AIM IMMUNOTECH INC based exclusively on its fundamental and basic technical indicators. By analyzing AIM IMMUNOTECH's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of AIM IMMUNOTECH's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of AIM IMMUNOTECH. We calculate exposure to AIM IMMUNOTECH's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AIM IMMUNOTECH's related companies.AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida. Aim Immunotech operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 21 people.
AIM IMMUNOTECH Growth Indicators
Investing in growth stocks can be very risky. If the company such as AIM IMMUNOTECH does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 56 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AIM IMMUNOTECH. If investors know AIM will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AIM IMMUNOTECH listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of AIM IMMUNOTECH INC is measured differently than its book value, which is the value of AIM that is recorded on the company's balance sheet. Investors also form their own opinion of AIM IMMUNOTECH's value that differs from its market value or its book value, called intrinsic value, which is AIM IMMUNOTECH's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AIM IMMUNOTECH's market value can be influenced by many factors that don't directly affect AIM IMMUNOTECH's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AIM IMMUNOTECH's value and its price as these two are different measures arrived at by different means. Investors typically determine if AIM IMMUNOTECH is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AIM IMMUNOTECH's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.